newsfilter
← Latest News
GlobeNewswire·

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates

Results support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterol VXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S.